Sara Deshpande
General Partner @ Maven Ventures
San Francisco, United States
Sara Deshpande is a General Partner at Maven Ventures, a seed stage venture firm investing in tech companies addressing emerging consumer behavior and trends with $200 million AUM across five funds. At Maven, Sara and the team identify and back bold founders with a vision worth fighting for and help them unlock their potential to change the world,building iconic brands like Zoom and Cruise. Sara specializes in consumer software including digital health and personalized medicine, consumer applications of AI, consumer climate, family tech, and other high-growth consumer sectors. At Maven, Sara has led pioneering investments at the Seed stage in companies including Daybreak Health, Hello Heart, Carrot Fertility, Nest Genomics, and Wildtype. Sara has been at Maven for a decade since joining as the first employee. She previously worked with startups around the globe, including at The Idea Village in New Orleans, helping founders articulate and achieve a bold vision against all odds. She is Lecturer in Management at the Stanford GSB where she teaches an MBA elective course on startups and is a regular contributor to Forbes on Venture Capital. Earlier in her career, Sara was a management consultant in the Healthcare Strategy practice at Deloitte. Sara graduated from Xavier University with a B.S. in Finance and received her M.B.A. from Stanford.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 16%
Last updated:
For AI agents: llms.txt
Industries Sara Deshpande invests in
Stages Sara Deshpande invests in
Countries Sara Deshpande invests in
Investment Focus
Industry
- Health Care 5 (26%)
- Mobile 3 (16%)
- Software 3 (16%)
- Internet 2 (11%)
- Wellness 2 (11%)
Stage
- Seed 8 (42%)
- Series A 3 (16%)
- Series B 3 (16%)
- Series C 3 (16%)
- Series D 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Medeloop
|
Medeloop accelerates breakthrough discoveries through novel deep AI model explainability techniques built on top of a comprehensive data linkage infrastructure. Medeloop is a one of a kind platform that seamlessly links, harmonizes, and analyzes massive amounts of health data. We are pioneering AI techniques that find biomarkers for clinicalresearchers, helping break down barriers to save lives.For Researchers: Our platform shortens the clinical research process using advanced AI techniques that provide research hypotheses for even the most understudied diseases.All of your data, all in one place. Cleaned, organized and analyzed. Medeloop transforms the research approach, enabling researchers to publish more and publish faster.For Research Participants: Our patient-facing app encourages the public to take control of their health and contribute to life-changing medical research.You always have access to view your health information and how it is being utilized. | $15.5M / Series A / Nov 13, 2024 | |
The Bot Company
|
The Bot Company a household robot startup. | $150M / Seed / May 13, 2024 | |
Perplexity
|
Perplexity is a search engine platform that uses artificial intelligence to provide large language models and search engines. The company's platform enables the development of beneficial artificial general intelligence, as well as an open-source environment that is accessible to the public, allowing clients to develop skills and knowledge inartificial intelligence. | $62.7M / Series C / Apr 23, 2024 | |
|
Medeloop
|
Medeloop accelerates breakthrough discoveries through novel deep AI model explainability techniques built on top of a comprehensive data linkage infrastructure. Medeloop is a one of a kind platform that seamlessly links, harmonizes, and analyzes massive amounts of health data. We are pioneering AI techniques that find biomarkers for clinicalresearchers, helping break down barriers to save lives.For Researchers: Our platform shortens the clinical research process using advanced AI techniques that provide research hypotheses for even the most understudied diseases.All of your data, all in one place. Cleaned, organized and analyzed. Medeloop transforms the research approach, enabling researchers to publish more and publish faster.For Research Participants: Our patient-facing app encourages the public to take control of their health and contribute to life-changing medical research.You always have access to view your health information and how it is being utilized. | $8M / Seed / Sep 20, 2023 | |
Daybreak Health
|
The Daybreak Health startup uses a mobile app to connect teens to teen-specialized therapists. Daybreak Health specializes in providing online counseling services, especially for teens, helping to stabilize their mental fitness. The company was founded in 2019 and is headquartered in San Francisco, California, United States. | $13M / Series B / Aug 08, 2023 | |
Nest Genomics (YC W22)
|
Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale. | $8.5M / Seed / Jan 10, 2023 | |
twine
|
Twine is a platform for deep networking, designed for virtual events and remote teams. | Venture - Series Unknown / Jul 21, 2022 | |
Kinside (Acquired by UrbanSitter in 2025)
|
Kinside gives parents everything they need to make work work: from securing a spot for your child, to paying for care online, and accessing tax savings and contributions from your employer. | $12M / Series A / Jun 07, 2022 | |
Gametime
|
Gametime sells last-minute tickets to the most popular events in sports, music, and theater. It makes finding the perfect live experience remarkably fast and easy. They curate an epic list of the most amazing possibilities in the city has to offer. Once the client selects their event it will examine over 10,000 potential seats and present them withthe 50 best values to select.Each curated seat option includes a panoramic high-resolution photo so their client can experience the actual view from their section. Navigate to the seat map to see price versus the location comparisons with true-to-life, full-color venue maps. Gametime delivers the tickets directly to the client's phone. Now they are offering sports, concerts, and theater events across the United States and Canada. | $30M / Series C / May 26, 2022 | |
Hello Heart
|
Hello Heart is a best in class solution that empowers people to understand and improve their heart health - the #1 cost factor for employers. The program is clinically based and targets people with high blood pressure. Each of our users receives a wireless blood pressure monitor and real-time personalized tips on their smartphone. It is easy to useand helps participants improve their heart health in a fun and engaging way. | $70M / Series D / May 02, 2022 | |
| See all 19 investments → | |||
Co-Investors
About Maven Ventures
Maven is a seed stage venture firm investing in tech companies addressing emerging consumer behavior and trends. The Maven team identifies and backs bold founders with a vision worth fighting for, then helps founders unlock their potential to change the world, building iconic brands like Zoom and Cruise. Maven maintains a concentrated investmentstrategy, making only 6-8 core investments each year. 16% of Maven companies have achieved an exit or valuation at $500M or more, 10x industry average.
Maven Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
James Scheinman
Founding Managing Partner
|
|||
Robert Ravanshenas
Investment Partner
|
|||
|
Sara Deshpande
General Partner
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sara Deshpande invest in?
Sara Deshpande invests primarily in Health Care, Mobile and Software startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Sara Deshpande last invest?
The most recent investment recorded for Sara Deshpande closed in Nov 2024. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
